NCT01803321View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Systemic Juvenile Idiopathic Arthritis

Interventions

DRUG

rilonacept (IL-1 Trap)

OTHER

Placebo

Trial Locations (9)

Unknown

Los Angeles

Wilmington

Chicago

Hackensack

Long Island City

Cincinnati

Cleveland

Dallas

Seattle

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01803321 - Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) | Biotech Hunter | Biotech Hunter